The number of class-action lawsuits claiming securities fraud committed by life sciences companies leveled off last year, but a new trend emerged — unlike in the past, when most suits targeted small-cap companies, more cases involved drug or device makers with market caps of $500 million or more.

A total of 86 class action securities lawsuits were filed against life sciences companies in 2018, a drop from 88 lawsuits filed the year before. Even so, this still represented a 352 percent rise from 19 such lawsuits that were filed in 2013, according to the Dechert law firm, which conducted the latest analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy